Botulinum Neurotoxins and Nervous System Future Challenges for Novel Indications
Botulinum Neurotoxins and Nervous System Future Challenges for Novel Indications
English[eng]
botulinum toxin||limb tremors||muscle selection||biological effect||various cell types||neurotransmitter||dermatology||novel indication||botulinum neurotoxin||masticatory system||maxillofacial bone||dental occlusion||orthognathic surgery||sialorrhoea||drooling||salivary glands||swallowing||eccrine glands||onabotulinumtoxin A||incobotulinumtoxin A||botulinum neurotoxins||botulinum neurotoxin serotype A||heavy chain||botulinum neurotoxin serotype a heavy chain (BoNT/A HC)||spinal cord injury (SCI)||nerve regeneration||growth associated protein 43 (GAP-43)||superior cervical ganglion 10 (SCG10)||neuronal processes||neural regeneration||Schwann cells||glia||spinal cord||immunohistochemistry||allodynia||weight bearing||sciatic static index||walking track analysis||itch||SNARE||VAMP||mast cells||compound 48/80||chloroquine||spasticity||botulinum toxin type A||appropriate treatment||Therapeutic Index||pruritus||antipruritic||clinical||experimental||BoNT/A||astroglia||interleukins||microglia||TLR2||TLR4||Snap-23||pain||cerebral palsy||botulinum toxin A||complex regional pain syndrome||lumbar sympathetic ganglion block||chronic pelvic pain||overactive detrusor||vaginism||temporomandibular joint dislocation||lateral pterygoid muscle||botulinum toxin therapy||synaptic transmission||SNAP-25||epilepsy||Parkinson’s disease||neurotransmission blockade||electrical activity||prion disease||new indications||formulation||delivery||refractory chronic migraine||tension headache||medication overuse headache||prophylactic treatment||XEOMIN®||BTX||central neuropathic pain||spinal cord injury||post-stroke shoulder pain||mouse test||Clostridium tetani||botulinum antitoxin||food safety||abobotulinumtoxinA||upper limb spasticity||post-stroke||early use||ONTIME||clinical trial||human||urodynamics||botulinum neurotoxin-A||basal ganglia||interspecies differences in motor behavior||mouse||rat||interneurons||hand tremor||treatment||electromyography||kinematics||essential tremor||dystonic tremor||tremor||movement disorders||Botulinum toxin||upper limb biomechanics||joint biomechanics||diagnostic guidance||clinical decision support||spastic paresis||electrical stimulation||stroke management||rehabilitation||hand||n/a
English[eng]
botulinum toxin||limb tremors||muscle selection||biological effect||various cell types||neurotransmitter||dermatology||novel indication||botulinum neurotoxin||masticatory system||maxillofacial bone||dental occlusion||orthognathic surgery||sialorrhoea||drooling||salivary glands||swallowing||eccrine glands||onabotulinumtoxin A||incobotulinumtoxin A||botulinum neurotoxins||botulinum neurotoxin serotype A||heavy chain||botulinum neurotoxin serotype a heavy chain (BoNT/A HC)||spinal cord injury (SCI)||nerve regeneration||growth associated protein 43 (GAP-43)||superior cervical ganglion 10 (SCG10)||neuronal processes||neural regeneration||Schwann cells||glia||spinal cord||immunohistochemistry||allodynia||weight bearing||sciatic static index||walking track analysis||itch||SNARE||VAMP||mast cells||compound 48/80||chloroquine||spasticity||botulinum toxin type A||appropriate treatment||Therapeutic Index||pruritus||antipruritic||clinical||experimental||BoNT/A||astroglia||interleukins||microglia||TLR2||TLR4||Snap-23||pain||cerebral palsy||botulinum toxin A||complex regional pain syndrome||lumbar sympathetic ganglion block||chronic pelvic pain||overactive detrusor||vaginism||temporomandibular joint dislocation||lateral pterygoid muscle||botulinum toxin therapy||synaptic transmission||SNAP-25||epilepsy||Parkinson’s disease||neurotransmission blockade||electrical activity||prion disease||new indications||formulation||delivery||refractory chronic migraine||tension headache||medication overuse headache||prophylactic treatment||XEOMIN®||BTX||central neuropathic pain||spinal cord injury||post-stroke shoulder pain||mouse test||Clostridium tetani||botulinum antitoxin||food safety||abobotulinumtoxinA||upper limb spasticity||post-stroke||early use||ONTIME||clinical trial||human||urodynamics||botulinum neurotoxin-A||basal ganglia||interspecies differences in motor behavior||mouse||rat||interneurons||hand tremor||treatment||electromyography||kinematics||essential tremor||dystonic tremor||tremor||movement disorders||Botulinum toxin||upper limb biomechanics||joint biomechanics||diagnostic guidance||clinical decision support||spastic paresis||electrical stimulation||stroke management||rehabilitation||hand||n/a